Mr. Sarney has an MBA from Boston University and has spent more than 15 years working with biotechnology companies.
Avaxia Biologics is a biopharmaceutical company developing therapies for gastroenterological and inflammatory bowel disease applications.
More Articles on Gastroenterology:
NPS Pharmaceuticals’ Short Bowel Syndrome Treatment Shows Promise
RedHill Biopharma Seeks Patients for Phase III Crohn’s Disease Treatment Drug Trial
Kanawha Valley Gastroenterology Associates Selects Benchmark Systems EHR
